^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CLIC-1901
i
Other names: CLIC-1901, CLIC1901, autologous anti-CD19 chimeric antigen receptor T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Ottawa Hospital Research Institute
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
6ms
CLIC-01: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=60, Recruiting, Ottawa Hospital Research Institute | Trial completion date: Oct 2022 --> Oct 2037 | Trial primary completion date: Oct 2022 --> Oct 2024
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • CLIC-1901
over1year
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. (PubMed, Front Immunol)
We report initial results from a single-arm, open-label study to determine the safety and efficacy of in-house manufactured CD19 CAR-T cells (entitled CLIC-1901) in participants with relapsed/refractory CD19 positive hematologic malignancies...Participants underwent lymphodepletion with fludarabine and cyclophosphamide, followed by infusion of non-cryopreserved CAR-T cells...Our experience may provide helpful guidance for other jurisdictions seeking to create feasible and sustainable CAR-T cell programs in research-oriented yet resource-constrained settings. https://clinicaltrials.gov/ct2/show/NCT03765177, identifier NCT03765177.
Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • fludarabine IV • CLIC-1901
2years
New P2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
CLIC-1901
Share via
